Tecentriq (atezolizumab) 1200 mg/20 mL concentrate for solution for infusion — original (F. Hoffmann-La Roche, Switzerland) Urinary epithelial carcinoma. Targeted cancer therapy. Delivery of medications from Europe within 4-5 days, storage conditions observed, payment upon receipt +380996042415 Viber, WhatsApp.

Urothelial carcinoma:

Treatment of adult patients with locally advanced or metastatic urothelial carcinoma:

• For those who are unsuitable for cisplatin-containing chemotherapy and whose tumor expresses PD-L1 (immune cells stained with PD-L1 that infiltrate the tumor and cover ? 5% of the tumor area), or
• For those who are unsuitable for any platinum-containing chemotherapy, regardless of PD-L1 expression level by the tumor.

Non-pediatric cell lung cancer (NPLC):

First-line treatment as monotherapy for adult patients with metastatic non-pediatric cell lung cancer (NPLC) with high PD-L1 expression (PD-L1-stained tumor cells ? 50% or stained immune cells infiltrating the tumor and covering ? 10% of the tumor area) and no EGFR or ALK tumor genomic aberrations.

First-line treatment in combination with bevacizumab, paclitaxel, and carboplatin for adult patients with metastatic non-squamous NPLC without EGFR or ALK tumor genomic aberrations.

First-line treatment in combination with paclitaxel associated with protein, and carboplatin for adult patients with metastatic nonsquamous NRLC without EGFR or ALK genomic aberrations.

Treatment of adult patients with metastatic NRLC who have disease progression during or after platinum-based chemotherapy. Patients with EGFR- or ALK-positive tumors should be monitored for disease progression on approved therapy for advanced small cell lung cancer (ASCLC) with these aberrations before initiating Tecentriq®.

Ambulatory Cell Lung Cancer:

First-line treatment in combination with carboplatin and etoposide for adult patients with advanced small cell lung cancer (ASCLC).

Hepatocellular Carcinoma:

Treatment in combination with bevacizumab for patients with unresectable or metastatic hepatocellular carcinoma who have not previously received systemic therapy.